Qiagen disclosed to advisers that it is evaluating strategic options amid reported interest from potential buyers, according to Bloomberg-sourced coverage; shareholders drove the stock back toward $50 after the report. The company has held talks with several potential suitors and is assessing preliminary interest, echoing past takeover speculation dating to Thermo Fisher’s 2020 approach. Analysts at J.P. Morgan and others note Qiagen’s diagnostics portfolio makes it an attractive target; management has not commented formally. Market reaction underscores continued consolidation pressure in life‑science tools and diagnostics.